CatalystMarker
← board

ABVC

distress 6/10 · elevated risk
$1.180%today-70% from 52w high
abvcpharma.com16 employeesFremont, CABiotechnology
Revenue
pre-revenue
Liquidity
$2M
Runway
0.6 yrs
Shares 1y
+10%

Price & events

-43.3% over 6M
$0.91$1.49$2.08Jan 26Apr 26Jul 26662k
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-2.5%
1W
-9.9%
1M
+3.5%
3M
-42.7%
6M
-61.6%
1Y
+49.0%
2Y
-97.6%
5Y
-97.7%
All

Overview

Market Cap
$30.68M
Volume
7.61K
52 Week Range
$0.91 – $3.97
Total Shares
26.00M
Float Shares
20.44M
Short %
1.73%
% Held by Insiders
18.57%
% Held by Institutions
3.14%
RVOL
0.05x
Beta
0.54

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 26,000,442 · 9 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.